Psoriasis News and Research

Latest Psoriasis News and Research

avVaa World Health Care Products to launch third Direct TV Media Test

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced their third Direct TV Media Test is scheduled to launch on Thursday October 29.

24 Oct 2009

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Based on an extensive review of the highest quality scientific literature on psoriasis and the opinion of recognized psoriasis experts, the American Academy of Dermatology (Academy) has released new guidelines of care for the management and treatment of psoriasis with ultraviolet (UV) light therapy, also known as phototherapy. Recommendations for the use of the most common forms of UV light therapy, as stand-alone treatments or in conjunction with other therapies, were outlined, including patient considerations.

23 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Update from SemBioSys Genetics regarding Botaneco Specialty Ingredients

SemBioSys Genetics Inc. today announced that Advitech Inc. ("Advitech") has entered into a definitive agreement to acquire all of the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by SemBioSys and Avrio Ventures Limited Partnership ("Avrio").

21 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Discovery may yield better understanding of protective gut-dwelling bacteria

Medical researchers have long suspected that obscure bacteria living within the intestinal tract may help keep the human immune system in balance. An international collaboration co-led by scientists at NYU Langone Medical Center has now identified a bizarre-looking microbial species that can single-handedly spur the production of specialized immune cells in mice.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

National Biological to market Quantel's 308 Excimer System in the U.S.

Quantel SA (Euronext: QUA), a leading manufacturer of solid state lasers, announced today that it has entered into a Distribution Agreement with National Biological, a leading researcher and developer of light-based systems for medical and cosmetic treatments, for Quantel's 308 Excimer System for monochromatic UVB treatment of psoriasis and vitiligo in the United States.

15 Oct 2009

NexMed completes its post hoc analysis of NM100060

NexMed, Inc., a developer of products based on the NexACT® technology, today announced that it has completed its post hoc analysis of NM100060, the Company’s topically-applied treatment for onychomycosis, commonly known as nail fungus. Based on this analysis, NexMed seeks to pursue signing a partner for further development of the product.

15 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Kevetrin reduces tumor volume by 72%: Cellceutix

October is breast cancer awareness month with many supporters touting pink ribbons, but in health stocks investors are watching the market closely for news of new drugs in various stages of testing. Recently, Cellceutix announced its pharmaceutical compound Kevetrin reduced tumor volume by 72%, giving new hope for breast cancer patients.

6 Oct 2009

New consumer At-Home Skin Typing and Analysis Kit unveiled

Reveal Sciences, LLC, a cosmetics and aesthetics innovation company pioneering breakthrough skin care diagnostics, has announced the launch of the new consumer At-Home Skin Typing and Analysis Kit.

5 Oct 2009

Psoriasis News and Research

Latest Psoriasis News and Research

avVaa World Health Care Products to launch third Direct TV Media Test

New guidelines from American Academy of Dermatology for treatment of psoriasis with ultraviolet light therapy

Celgene announces fiscal 2009 third-quarter results

Schering-Plough announces 2009 third quarter financial results

Update from SemBioSys Genetics regarding Botaneco Specialty Ingredients

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

RA patients who adhere to their prescription drug regimen have better outcome: Study

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Discovery may yield better understanding of protective gut-dwelling bacteria

Research programme to develop immunological biomarkers for chronic inflammatory diseases

National Biological to market Quantel's 308 Excimer System in the U.S.

NexMed completes its post hoc analysis of NM100060

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Johnson & Johnson announces financial results for the third quarter of 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Schering-Plough receives FDA recommendation approval for PEGINTRON

Kevetrin reduces tumor volume by 72%: Cellceutix

New consumer At-Home Skin Typing and Analysis Kit unveiled

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in